

Last day of trading in BTA 1 in 2cureX AB

In May 2019, 2cureX AB (“2cureX”) conducted a rights issue of shares in which the general public was given the opportunity to subscribe for shares. Through the rights issue, a total of 2,070,000 shares were issued. The rights issue has now been fully registered at the Swedish Companies Registration Office. Last day of trading in BTA 1 (paid-up for shares) will be the 2nd of July, 2019 and the stop date will be the 4th of July, 2019.

Two partial registrations of a total of 2,070,000 shares have been registered at the Swedish Companies Registration Office. The shares that are covered by the first partial registration and that refer to 1 922 474 BTA 1 are estimated to be distributed to each VP account/depot on the 7th of July, 2019. The shares that are covered by the second partial registration and that refer to 147 526 BTA 2, which have not been subject to trading, will be converted into shares and distributed to each VP account/depot on the 17th of July, 2019.

After the registrations, the number of shares in 2cureX at the Swedish Companies Registration Office will be 12,420,000 shares. The share capital after the registration amounts to SEK 1,242,000.00.

Financial adviser, issuing agent and legal adviser

Sedermera Fondkommission is the financial advisor and issuing agent to 2cureX in connection with the rights issue. Markets & Corporate Law acts as the legal advisor.

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer

E-mail: ot@2curex.com

Telephone: +45 22 11 53 99

www.2curex.com

Certified Adviser

Sedermera Fondkommission

E-mail: ca@sedermera.se

Telephone: +46 40 615 14 15

About 2cureX

2cureX has developed a test called IndiTreat[®] (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat[®] establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour. From a large panel of approved cancer treatments IndiTreat[®] selects the best treatment for the individual patient. IndiTreat[®] is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat[®] is currently being clinically validated in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical studies are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).